Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ • Healthcare
November 18, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, Regeneron Pharmaceuticals, Inc. keeps $38 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Jan 28
in 70 daysQ1 2027% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Regeneron Pharmaceuticals beat expectations on both the top and bottom line in the third fiscal quarter of 2026, reported October 30, 2026, with adjusted EPS of $20.07 topping the $16.51 estimate (+21.6%) and revenue of $5.116 billion topping the $4.584 billion estimate (+11.6%). Revenue rose ~36% to about $5.1 billion (up from roughly $3.8 billion a year ago), while net income increased ~34% to nearly $1.9 billion (up from about $1.5 billion a year ago), alongside adjusted EPS up ~70% from $11.83. Profitability remained high in the quarter, with gross margin at roughly 89% and operating margin at about 40%, as gross profit reached around $4.5 billion and operating income came in near $2.0 billion. The company generated operating cash flow of about $1.8 billion and returned cash through roughly $399.7 million of share repurchases and about $95.7 million of dividends. For the next period, consensus calls for EPS of $20.87 on revenue of $5.752 billion.
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. develops and markets biologic medicines as a biotechnology company listed on NASDAQ under REGN. Its portfolio spans eye disease, immunology, oncology, cardiovascular and infectious-disease therapies, and it generated $14.3 billion of revenue in FY2025 through a portfolio of marketed drugs and clinical-stage product candidates.
Today's Snapshot
REGN closed 1.3% below yesterday's close, in line with a weaker sector. Trading was lighter than usual, with volume about two-thirds of its usual level. Regeneron won European approval to offer flexible dosing for Libtayo, its cancer drug.
Trading Volume
Below 10d avg (982.2K)
672.9K
vs S&P 500 Today
Underperforming Market
-1.02%
Updated: November 18, 2026 at 21:15 UTC
REGN Headlines
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$773.10 - $936.76Buy
- RSI (14)64.39Neutral
- Stochastic %K (14, 3, 3)76.71Neutral
- MACD Level (12, 26)40.55Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.